1:34 PM
 | 
Jul 12, 2018
 |  BC Extra  |  Clinical News

Zogenix market cap grows with second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) gained $9.60 (21%) to $55.90 on Thursday, adding about $338 million in market cap, after it reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint in its second Phase III trial, Study 1504, to treat Dravet syndrome.

Daily 0.5...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >